{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:38:56Z","timestamp":1792456736899,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02328-2","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:15:17Z","timestamp":1784823317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Do new guidelines enable a more accurate comparison of [18F]FDG PET\/CT features with histopathology in primary breast cancer?"],"prefix":"10.1186","volume":"28","author":[{"given":"A. R.","family":"Sharkey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiu Yeung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Funso-Fayomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. E.","family":"Pinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J. R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2328_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/jjco\/hyn019","volume":"38","author":"S Ueda","year":"2008","unstructured":"Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18f-fluorodeoxyglucose positron emission tomography\/computed tomography fusion imaging (18F-FDG PET\/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250\u20138. https:\/\/doi.org\/10.1093\/jjco\/hyn019.","journal-title":"Jpn J Clin Oncol"},{"key":"2328_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1200\/jco.2002.20.2.379","volume":"20","author":"R Bos","year":"2002","unstructured":"Bos R, van der Hoeven JJM, van der Groep WE, van der P, van Comans DPJ. Biologic correlates of 18 fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379\u201387. https:\/\/doi.org\/10.1200\/jco.2002.20.2.379.","journal-title":"J Clin Oncol"},{"key":"2328_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4103\/ijnm.ijnm_94_18","volume":"34","author":"ZA Abubakar","year":"2019","unstructured":"Abubakar ZA, Akepati NKR, Bikkina P. Correlation of maximum standardized uptake values in 18F-fluorodeoxyglucose positron emission tomography-computed tomography scan with immunohistochemistry and other prognostic factors in breast cancer. Indian J Nucl Med : IJNM : Off J Soc Nucl Med India. 2019;34:10\u20133. https:\/\/doi.org\/10.4103\/ijnm.ijnm_94_18.","journal-title":"Indian J Nucl Med : IJNM : Off J Soc Nucl Med India"},{"key":"2328_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/bjs.6459","volume":"96","author":"A Gil-Rendo","year":"2009","unstructured":"Gil-Rendo A, Mart\u00ednez\u2010Regueira F, Zornoza G, Garc\u00eda\u2010Velloso MJ, Beorlegui C, Rodriguez\u2010Spiteri N. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96:166\u201370. https:\/\/doi.org\/10.1002\/bjs.6459.","journal-title":"Br J Surg"},{"key":"2328_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","volume":"38","author":"D Groheux","year":"2011","unstructured":"Groheux D, Giacchetti S, Moretti J-L, Porcher R, Espi\u00e9 M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426\u201335. https:\/\/doi.org\/10.1007\/s00259-010-1640-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2328_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s00330-013-3037-1","volume":"24","author":"HR Koo","year":"2014","unstructured":"Koo HR, Park JS, Kang KW, Cho N, Chang JM, Bae MS, et al. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Radiol. 2014;24:610\u20138. https:\/\/doi.org\/10.1007\/s00330-013-3037-1.","journal-title":"Eur Radiol"},{"key":"2328_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.remnie.2021.01.004","volume":"41","author":"T Sengoz","year":"2022","unstructured":"Sengoz T, Karakaya YA, Gultekin A, Yaylali O, Senol H, Yuksel D. Relationships of 18F-FDG uptake by primary tumors with prognostic factors and molecular subtype in ductal breast cancer. Rev Espa\u00f1ola Med Nucl e Imagen Mol (Engl Ed). 2022;41:32\u20138. https:\/\/doi.org\/10.1016\/j.remnie.2021.01.004.","journal-title":"Rev Espa\u00f1ola Med Nucl e Imagen Mol (Engl Ed)"},{"key":"2328_CR8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00259-002-0880-8","volume":"29","author":"A Buck","year":"2002","unstructured":"Buck A, Schirrmeister H, K\u00fchn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317\u201323. https:\/\/doi.org\/10.1007\/s00259-002-0880-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2328_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2967\/jnumed.108.060459","volume":"51","author":"JR Osborne","year":"2010","unstructured":"Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, et al. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. J Nucl Med. 2010;51:543\u201350. https:\/\/doi.org\/10.2967\/jnumed.108.060459.","journal-title":"J Nucl Med"},{"key":"2328_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13058-016-0793-2","volume":"19","author":"D Groheux","year":"2017","unstructured":"Groheux D, Martineau A, Teixeira L, Espi\u00e9 M, de Cremoux P, Bertheau P, et al. 18FDG-PET\/CT for predicting the outcome in ER+\/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis. Breast Cancer Res. 2017;19:3. https:\/\/doi.org\/10.1186\/s13058-016-0793-2.","journal-title":"Breast Cancer Res"},{"key":"2328_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.ejrad.2016.02.015","volume":"85","author":"K Kitajima","year":"2016","unstructured":"Kitajima K, Yamano T, Fukushima K, Miyoshi Y, Hirota S, Kawanaka Y, et al. Correlation of the SUVmax of FDG-PET and ADC values of diffusion-weighted MR imaging with pathologic prognostic factors in breast carcinoma. Eur J Radiol. 2016;85:943\u20139. https:\/\/doi.org\/10.1016\/j.ejrad.2016.02.015.","journal-title":"Eur J Radiol"},{"key":"2328_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13550-023-00953-y","volume":"13","author":"CM de Mooij","year":"2023","unstructured":"de Mooij CM, Ploumen RAW, Nelemans PJ, Mottaghy FM, Smidt ML, van Nijnatten TJA. The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis. EJNMMI Res. 2023;13:5. https:\/\/doi.org\/10.1186\/s13550-023-00953-y.","journal-title":"EJNMMI Res"},{"key":"2328_CR13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1200\/jco.2022.40.16_suppl.1087","volume":"40","author":"G Viale","year":"2022","unstructured":"Viale G, Niikura N, Tokunaga E, Aleynikova O, Hayashi N, Sohn J, et al. Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics. J Clin Oncol. 2022;40:1087\u20131087. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.1087.","journal-title":"J Clin Oncol"},{"key":"2328_CR14","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/cancers13112824","volume":"13","author":"E Agostinetto","year":"2021","unstructured":"Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M, Aftimos P, et al. HER2-low breast cancer: molecular characteristics and prognosis. Cancers. 2021;13:2824. https:\/\/doi.org\/10.3390\/cancers13112824.","journal-title":"Cancers"},{"key":"2328_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","volume":"7","author":"F Schettini","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, Par\u00e9 L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7:1. https:\/\/doi.org\/10.1038\/s41523-020-00208-2.","journal-title":"NPJ Breast Cancer"},{"key":"2328_CR16","doi-asserted-by":"publisher","first-page":"175883592311528","DOI":"10.1177\/17588359231152842","volume":"15","author":"E Nicol\u00f2","year":"2023","unstructured":"Nicol\u00f2 E, Bielo LB, Curigliano G, Tarantino P. The HER2-low revolution in breast oncology: steps forward and emerging challenges. Ther Adv M\u00e9d Oncol. 2023;15:17588359231152842. https:\/\/doi.org\/10.1177\/17588359231152842.","journal-title":"Ther Adv M\u00e9d Oncol"},{"key":"2328_CR17","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","volume":"51","author":"SC Vaz","year":"2024","unstructured":"Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:2706\u201332. https:\/\/doi.org\/10.1007\/s00259-024-06696-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2328_CR18","unstructured":"Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening [Internet]. 2021. https:\/\/www.rcpath.org\/static\/4b16f19c-f7bd-456c-b212f557f8040f66\/G150-Non-op-reporting-breast-cancer-screening.pdf"},{"key":"2328_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"ELSTON","year":"1991","unstructured":"ELSTON, CW, ELLIS IO. pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow\u2010up. Histopathology. 1991;19:403\u201310. https:\/\/doi.org\/10.1111\/j.1365-2559.1991.tb00229.x.","journal-title":"Histopathology"},{"key":"2328_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/1754-9485.13114","volume":"65","author":"E Arslan","year":"2021","unstructured":"Arslan E, Trabulus DC, Mermut \u00d6, \u015eavl\u0131 TC, \u00c7ermik TF. Alternative volumetric PET parameters for evaluation of breast cancer cases with 18F-FDG PET\/CT imaging: Metabolic tumour volume and total lesion glycolysis. J M\u00e9d Imaging Radiat Oncol. 2021;65:38\u201345. https:\/\/doi.org\/10.1111\/1754-9485.13114.","journal-title":"J M\u00e9d Imaging Radiat Oncol"},{"key":"2328_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10549-013-2687-7","volume":"141","author":"T Kadoya","year":"2013","unstructured":"Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M. Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography\/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study. Breast Cancer Res Treat. 2013;141:269\u201375. https:\/\/doi.org\/10.1007\/s10549-013-2687-7.","journal-title":"Breast Cancer Res Treat"},{"key":"2328_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.remnie.2017.12.003","volume":"37","author":"AM Garcia-Vicente","year":"2018","unstructured":"Garcia-Vicente AM, P\u00e9rez-Beteta J, Amo-Salas M, Molina D, Jimenez-Londo\u00f1o GA, Soriano-Castrej\u00f3n AM, et al. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline 18 F-FDG PET\/CT in breast cancer with neoadjuvant chemotherapy indication. Rev Espa\u00f1ola Med Nucl e Imagen Mol (Engl Ed). 2018;37:73\u20139. https:\/\/doi.org\/10.1016\/j.remnie.2017.12.003.","journal-title":"Rev Espa\u00f1ola Med Nucl e Imagen Mol (Engl Ed)"},{"key":"2328_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/mnm.0000000000001227","volume":"41","author":"K Pak","year":"2020","unstructured":"Pak K, Seok JW, Kim HY, Nguyen TL, Kim K, Kim SJ, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in breast cancer: a meta-analysis. Nucl Med Commun. 2020;41:824\u20139. https:\/\/doi.org\/10.1097\/mnm.0000000000001227.","journal-title":"Nucl Med Commun"},{"key":"2328_CR24","unstructured":"Radiologists TRC. of. Evidence-based indications for the use of PET-CT in the United Kingdom 2022. 2012."},{"key":"2328_CR25","doi-asserted-by":"publisher","first-page":"100006","DOI":"10.1016\/j.eanmj.2025.100006","volume":"1","author":"R Boellaard","year":"2025","unstructured":"Boellaard R, Herrmann K, Barrington SF, Cranston I, Mottaghy FM, Hoekstra CJ, et al. [18F]FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 3.0. EANM J. 2025;1:100006. https:\/\/doi.org\/10.1016\/j.eanmj.2025.100006.","journal-title":"EANM J"},{"key":"2328_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2328_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.52586\/4960","volume":"26","author":"J Liu","year":"2021","unstructured":"Liu J, Bian H, Zhang Y, Gao Y, Yin G, Wang Z, et al. Molecular subtype classification of breast cancer using established radiomic signature models based on 18F-FDG PET\/CT images. Front Biosci-Landmark. 2021;26:475\u201384. https:\/\/doi.org\/10.52586\/4960.","journal-title":"Front Biosci-Landmark"},{"key":"2328_CR28","doi-asserted-by":"publisher","first-page":"13409","DOI":"10.3390\/ijms232113409","volume":"23","author":"L Urso","year":"2022","unstructured":"Urso L, Manco L, Castello A, Evangelista L, Guidi G, Castellani M, et al. PET-derived radiomics and artificial intelligence in breast cancer: a systematic review. Int J Mol Sci. 2022;23:13409. https:\/\/doi.org\/10.3390\/ijms232113409.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2328_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.21203\/rs.3.rs-3145802\/v1","volume":"59","author":"H Ding","year":"2023","unstructured":"Ding H, Li Y, Liang T, Liao Y, Yu X, Duan X, et al. PET\/CT Radiomics integrated with clinical indexes as a tool to predict Ki67 in breast cancer: a pilot study. Nuclear Med Mol Imaging. 2023;59(3):164\u201373. https:\/\/doi.org\/10.21203\/rs.3.rs-3145802\/v1","journal-title":"Nuclear Med Mol Imaging"},{"key":"2328_CR30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/diagnostics12030694","volume":"12","author":"J-H Jo","year":"2022","unstructured":"Jo J-H, Chung HW, So Y, Yoo YB, Park KS, Nam SE, et al. FDG PET\/CT to predict recurrence of early breast invasive ductal carcinoma. Diagnostics. 2022;12:694. https:\/\/doi.org\/10.3390\/diagnostics12030694.","journal-title":"Diagnostics"},{"key":"2328_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/cam4.119","volume":"2","author":"GA Ulaner","year":"2013","unstructured":"Ulaner GA, Eaton A, Morris PG, Lilienstein J, Jhaveri K, Patil S, et al. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Med. 2013;2:725\u201333. https:\/\/doi.org\/10.1002\/cam4.119.","journal-title":"Cancer Med"},{"key":"2328_CR32","first-page":"120","volume":"6","author":"B Marinelli","year":"2015","unstructured":"Marinelli B, Espinet-Col C, Ulaner GA, McArthur HL, Gonen M, Jochelson M, et al. Prognostic value of FDG PET\/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. Am J Nucl Med Mol imaging. 2015;6:120\u20137.","journal-title":"Am J Nucl Med Mol imaging"},{"key":"2328_CR33","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3390\/cancers17071249","volume":"17","author":"D Groheux","year":"2025","unstructured":"Groheux D, Ferrer L, Vargas J, Martineau A, Borgel A, Teixeira L, et al. FDG-PET\/CT and multimodal machine learning model prediction of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. Cancers. 2025;17:1249. https:\/\/doi.org\/10.3390\/cancers17071249.","journal-title":"Cancers"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02328-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02328-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02328-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:40:24Z","timestamp":1792453224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02328-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2328"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02328-2","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"institutional approval was granted for this retrospective study without the requirement for retrospective consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"180"}}